Search results for "lupus anticoagulant"

showing 5 items of 15 documents

Neuroprotective effect of Fn14 deficiency is associated with induction of the granulocyte-colony stimulating factor (G-CSF) pathway in experimental s…

2010

Using a transgenic mouse model of ischemic stroke we checked for a possible interaction of antiphospholipid antibodies (aPL) which often cause thromboses as well as central nervous system (CNS) involvement under non-thrombotic conditions and the TWEAK/Fn14 pathway known to be adversely involved in inflammatory and ischemic brain disease. After 7 days, infarct volumes were reduced in Fn14 deficient mice and were further decreased by aPL treatment. This was associated with strongest increase of the endogenous neuroprotective G-CSF/G-CSF receptor system. This unexpected beneficial action of aPL is an example for a non-thrombogenic action and the double-edged nature of aPL.

MaleGenetically modified mouseImmunologyMice TransgenicBiologyNeuroprotectionReceptors Tumor Necrosis FactorBrain IschemiaMiceRandom AllocationTissue factorimmune system diseasesAntiphospholipid syndromeGranulocyte Colony-Stimulating FactormedicineAnimalsHumansImmunology and AllergyneoplasmsStrokeLupus anticoagulantmedicine.diseaseMice Inbred C57BLDisease Models AnimalNeurologyTWEAK ReceptorReceptors Granulocyte Colony-Stimulating FactorImmunologyAntibodies AntiphospholipidTumor necrosis factor alphaNeurology (clinical)Inflammation MediatorsGranulocyte colony-stimulating factor receptorSignal TransductionJournal of Neuroimmunology
researchProduct

Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different

1998

In order to clarify the coagulation profile accompanying ischemic stroke, which may have implications on therapeutic strategies, we performed a prospective study to evaluate the hemostatic parameters in the first 24 h after the onset of cortical atherothrombotic infarct and lacunar infarction. Twenty-seven patients with cortical atherothrombotic infarction and 27 patients with lacunar infarction, diagnosed on clinical and CT-scan criteria, had blood samples taken within the first 24 h after onset of the stroke, and before anticoagulant treatment had been started. Levels of fibrinogen, von Willebrand factor, D-dimers, prothrombin factors 1 + 2, anti-thrombin III, and C-protein and S-proteins…

Malemedicine.medical_specialtyFibrinogenBrain IschemiaVon Willebrand factorInternal medicinemedicineHumansProspective Studiescardiovascular diseasesProspective cohort studyStrokeAgedBlood coagulation testAged 80 and overHemostasisLupus anticoagulantbiologybusiness.industryThrombosisCerebral InfarctionGeneral MedicineMiddle Agedmedicine.diseaseCerebrovascular DisordersDementia Multi-InfarctNeurologyCoagulationHemostasisbiology.proteinCardiologyFemaleBlood Coagulation TestsNeurology (clinical)businessmedicine.drugNeurological Research
researchProduct

A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody

2002

The antiphospholipid syndrome (APS) was described in 1983 as a clinical entity characterized by venous and arterial thrombosis, thrombocytopenia, and recurrent fetal loss. The serological markers of APS are antiphospholipid antibodies (APLA) directed mainly against anionic phospholipids, usually cardiolipin but also phosphatidylserine. Some APLA exhibit lupus anticoagulant activity. Monoclonal gammopathy sometimes occurs with the presence of autoantibodies. In this paper, we describe a patient with the diagnosis of immunocytoma with an IgM, kappa paraprotein with apparent specificity against anionic phospholipids, and lupus anticoagulant activity, but no clinical signs of APS. We describe i…

Pathologymedicine.medical_specialtyImmunologymedicine.disease_causeSerologyAutoimmunityImmunoglobulin kappa-ChainsRheumatologyimmune system diseasesAntiphospholipid syndromemedicineHumansImmunology and AllergyGlycoproteinsLupus anticoagulantbiologybusiness.industryAutoantibodyWaldenstrom macroglobulinemiaMiddle Agedmedicine.diseaseTreatment OutcomeImmunoglobulin Mbeta 2-Glycoprotein ILupus Coagulation InhibitorImmunologyMonoclonalAntibodies Antiphospholipidbiology.proteinFemaleWaldenstrom MacroglobulinemiaAntibodybusinessParaproteinsRheumatology International
researchProduct

Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?

2021

Antiphospholipid syndrome (APS) is frequently associated with thrombocytopenia, in most cases mild and in the absence of major bleedings. In some patients with a confirmed APS diagnosis, secondary immune thrombocytopenia (ITP) may lead to severe thrombocytopenia with consequent major bleeding. At the same time, the presence of antiphospholipid antibodies (aPL) in patients with a diagnosis of primary ITP has been reported in several studies, although with some specific characteristics especially related to the variety of antigenic targets. Even though it does not enter the APS defining criteria, thrombocytopenia should be regarded as a warning sign of a “high risk” APS and thus thoroughly ev…

Pediatricsmedicine.medical_specialtyQH301-705.5medicine.drug_classMedicine (miscellaneous)thrombocytopeniaReviewGeneral Biochemistry Genetics and Molecular BiologyAntigenimmune system diseasesAntiphospholipid syndromehemic and lymphatic diseasesmedicineBiology (General)Antiphospholipid antibodies Antiphospholipid syndrome Immune thrombocytopenia Lupus anticoagulant ThrombocytopeniaLupus anticoagulantbiologybusiness.industryAnticoagulantantiphospholipid antibodiesmedicine.diseaseThrombosisImmune thrombocytopeniaVenous thrombosislupus anticoagulantimmune thrombocytopeniabiology.proteinAntibodybusinessAntiphospholipid antibodieantiphospholipid syndromeBiomedicines
researchProduct

Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins

2021

Antiphospholipid antibodies (aPL), assumed to cause antiphospholipid syndrome (APS), are notorious for their heterogeneity in targeting phospholipids and phospholipid-binding proteins. The persistent presence of Lupus anticoagulant and/or aPL against cardiolipin and/or β2-glycoprotein I have been shown to be independent risk factors for vascular thrombosis and pregnancy morbidity in APS. aPL production is thought to be triggered by–among other factors–viral infections, though infection-associated aPL have mostly been considered non-pathogenic. Recently, the potential pathogenicity of infection-associated aPL has gained momentum since an increasing number of patients infected with Severe Acu…

RNA virusesPulmonologyCoronavirusesPhysiology2405 ParasitologyAntibody Response030204 cardiovascular system & hematologyBiochemistrychemistry.chemical_compoundMedical Conditions0302 clinical medicineimmune system diseasesImmune PhysiologyMedicine and Health SciencesCardiolipinMedicineBiology (General)skin and connective tissue diseasesImmune ResponsePathology and laboratory medicineCOVIDVirus Testing0303 health sciencesLupus anticoagulantImmune System Proteinsbiologymedicine.diagnostic_test2404 MicrobiologyProteasesMedical microbiologyEnzymes3. Good healthInfectious DiseasesCoagulationVirusesSARS CoV 2PathogensAntibodyResearch ArticleSARS coronavirusQH301-705.5Immunology10208 Institute of Neuropathology610 Medicine & healthSARS-CoV-2; Respiratory infections; Virus testing; serine proteases; Antibody response; Autoantibodies; Blood plasma; ImmunoassaysResearch and Analysis MethodsMicrobiologyAntibodiesRespiratory Disorders03 medical and health sciences1311 GeneticsDiagnostic MedicineAntiphospholipid syndromeVirology1312 Molecular BiologyGeneticsImmunoassaysneoplasmsMolecular BiologyAutoantibodies030304 developmental biology030203 arthritis & rheumatology2403 ImmunologyPregnancyBiology and life sciencesbusiness.industryOrganismsViral pathogensAutoantibodyProteinsRC581-607medicine.diseaseMicrobial pathogenschemistry19ImmunoassayRespiratory InfectionsImmunology2406 VirologyEnzymologyImmunologic Techniquesbiology.protein570 Life sciences; biologyParasitologyImmunologic diseases. AllergySerine ProteasesbusinessPLOS Pathogens
researchProduct